| pubmed-article:21115860 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21115860 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:21115860 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:21115860 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:21115860 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:21115860 | lifeskim:mentions | umls-concept:C0278488 | lld:lifeskim |
| pubmed-article:21115860 | lifeskim:mentions | umls-concept:C0079083 | lld:lifeskim |
| pubmed-article:21115860 | lifeskim:mentions | umls-concept:C0205177 | lld:lifeskim |
| pubmed-article:21115860 | lifeskim:mentions | umls-concept:C0246415 | lld:lifeskim |
| pubmed-article:21115860 | lifeskim:mentions | umls-concept:C0728747 | lld:lifeskim |
| pubmed-article:21115860 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
| pubmed-article:21115860 | lifeskim:mentions | umls-concept:C0040808 | lld:lifeskim |
| pubmed-article:21115860 | lifeskim:mentions | umls-concept:C0302350 | lld:lifeskim |
| pubmed-article:21115860 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:21115860 | lifeskim:mentions | umls-concept:C0205250 | lld:lifeskim |
| pubmed-article:21115860 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:21115860 | pubmed:dateCreated | 2011-1-7 | lld:pubmed |
| pubmed-article:21115860 | pubmed:abstractText | Docetaxel-trastuzumab (TH) is effective therapy for HER2-amplified metastatic breast cancer (MBC). Preclinical findings of synergy between docetaxel, carboplatin, and trastuzumab (TCH) prompted a phase III randomized trial comparing TCH with TH in patients with HER2-amplified MBC. | lld:pubmed |
| pubmed-article:21115860 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21115860 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21115860 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21115860 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21115860 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21115860 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21115860 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21115860 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21115860 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21115860 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21115860 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21115860 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21115860 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:21115860 | pubmed:issn | 1527-7755 | lld:pubmed |
| pubmed-article:21115860 | pubmed:author | pubmed-author:SauterGuidoG | lld:pubmed |
| pubmed-article:21115860 | pubmed:author | pubmed-author:MackeyJohn... | lld:pubmed |
| pubmed-article:21115860 | pubmed:author | pubmed-author:SlamonDennis... | lld:pubmed |
| pubmed-article:21115860 | pubmed:author | pubmed-author:ValeroVicente... | lld:pubmed |
| pubmed-article:21115860 | pubmed:author | pubmed-author:CrownJohnJ | lld:pubmed |
| pubmed-article:21115860 | pubmed:author | pubmed-author:BuyseMarcM | lld:pubmed |
| pubmed-article:21115860 | pubmed:author | pubmed-author:FumoleauPierr... | lld:pubmed |
| pubmed-article:21115860 | pubmed:author | pubmed-author:MartinMiguelM | lld:pubmed |
| pubmed-article:21115860 | pubmed:author | pubmed-author:PressMichael... | lld:pubmed |
| pubmed-article:21115860 | pubmed:author | pubmed-author:von... | lld:pubmed |
| pubmed-article:21115860 | pubmed:author | pubmed-author:RivaAlessandr... | lld:pubmed |
| pubmed-article:21115860 | pubmed:author | pubmed-author:PegramMark... | lld:pubmed |
| pubmed-article:21115860 | pubmed:author | pubmed-author:EiermannWolfg... | lld:pubmed |
| pubmed-article:21115860 | pubmed:author | pubmed-author:ForbesJohnJ | lld:pubmed |
| pubmed-article:21115860 | pubmed:author | pubmed-author:RocheHenriH | lld:pubmed |
| pubmed-article:21115860 | pubmed:author | pubmed-author:PienkowskiTad... | lld:pubmed |
| pubmed-article:21115860 | pubmed:author | pubmed-author:Mrsic-Krmpoti... | lld:pubmed |
| pubmed-article:21115860 | pubmed:author | pubmed-author:Jagiello-Grus... | lld:pubmed |
| pubmed-article:21115860 | pubmed:author | pubmed-author:RolskiJanuszJ | lld:pubmed |
| pubmed-article:21115860 | pubmed:author | pubmed-author:TaupinHenryH | lld:pubmed |
| pubmed-article:21115860 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21115860 | pubmed:day | 10 | lld:pubmed |
| pubmed-article:21115860 | pubmed:volume | 29 | lld:pubmed |
| pubmed-article:21115860 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21115860 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21115860 | pubmed:pagination | 149-56 | lld:pubmed |
| pubmed-article:21115860 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:21115860 | pubmed:meshHeading | pubmed-meshheading:21115860... | lld:pubmed |
| pubmed-article:21115860 | pubmed:meshHeading | pubmed-meshheading:21115860... | lld:pubmed |
| pubmed-article:21115860 | pubmed:meshHeading | pubmed-meshheading:21115860... | lld:pubmed |
| pubmed-article:21115860 | pubmed:meshHeading | pubmed-meshheading:21115860... | lld:pubmed |
| pubmed-article:21115860 | pubmed:meshHeading | pubmed-meshheading:21115860... | lld:pubmed |
| pubmed-article:21115860 | pubmed:meshHeading | pubmed-meshheading:21115860... | lld:pubmed |
| pubmed-article:21115860 | pubmed:meshHeading | pubmed-meshheading:21115860... | lld:pubmed |
| pubmed-article:21115860 | pubmed:meshHeading | pubmed-meshheading:21115860... | lld:pubmed |
| pubmed-article:21115860 | pubmed:meshHeading | pubmed-meshheading:21115860... | lld:pubmed |
| pubmed-article:21115860 | pubmed:meshHeading | pubmed-meshheading:21115860... | lld:pubmed |
| pubmed-article:21115860 | pubmed:meshHeading | pubmed-meshheading:21115860... | lld:pubmed |
| pubmed-article:21115860 | pubmed:meshHeading | pubmed-meshheading:21115860... | lld:pubmed |
| pubmed-article:21115860 | pubmed:meshHeading | pubmed-meshheading:21115860... | lld:pubmed |
| pubmed-article:21115860 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21115860 | pubmed:articleTitle | Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. | lld:pubmed |
| pubmed-article:21115860 | pubmed:affiliation | Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. vvalero@mdanderson.org | lld:pubmed |
| pubmed-article:21115860 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21115860 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:21115860 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:21115860 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:21115860 | pubmed:publicationType | Clinical Trial, Phase III | lld:pubmed |
| entrez-gene:2064 | entrezgene:pubmed | pubmed-article:21115860 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:21115860 | lld:entrezgene |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:21115860 | lld:pubmed |
